254 related articles for article (PubMed ID: 30648449)
1. Clinical presentation, treatment, and outcomes of patients with central nervous system involvement in extranodal natural killer/T-cell lymphoma.
Nevel KS; Pentsova E; Daras M
Leuk Lymphoma; 2019 Jul; 60(7):1677-1684. PubMed ID: 30648449
[TBL] [Abstract][Full Text] [Related]
2. When do we need central nervous system prophylaxis in patients with extranodal NK/T-cell lymphoma, nasal type?
Kim SJ; Oh SY; Hong JY; Chang MH; Lee DH; Huh J; Ko YH; Ahn YC; Kim HJ; Suh C; Kim K; Kim WS
Ann Oncol; 2010 May; 21(5):1058-63. PubMed ID: 19850636
[TBL] [Abstract][Full Text] [Related]
3. Clinical analysis of patients with primary and secondary extranodal natural killer/T-cell lymphoma of central nervous system.
Li X; Yu H; Fu X; Zhang L; Li X; Li L; Wang X; Sun Z; Zhang X; Li Z; Wu J; Chang Y; Yan J; Zhou Z; Nan F; Wu X; Tian L; Zhang M
Hematol Oncol; 2023 Apr; 41(2):267-274. PubMed ID: 34061378
[TBL] [Abstract][Full Text] [Related]
4. Central nervous system involvement at initial diagnosis of extranodal NK/T-cell lymphoma: a retrospective study of a consecutive 12-year case series.
Wu W; Ren K; Li N; Luo Q; Zhou H; Hai T; Zou L
Ann Hematol; 2023 Apr; 102(4):829-839. PubMed ID: 36729147
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcomes and central nervous system relapse in extranodal natural killer/T-cell lymphoma.
Miyazaki K; Suzuki R; Oguchi M; Taguchi S; Amaki J; Maeda T; Kubota N; Maruyama D; Terui Y; Sekiguchi N; Takizawa J; Tsukamoto H; Murayama T; Ando T; Matsuoka H; Hasegawa M; Wada H; Sakai R; Kameoka Y; Tsukamoto N; Choi I; Masaki Y; Shimada K; Fukuhara N; Utsumi T; Uoshima N; Kagami Y; Asano N; Ejima Y; Katayama N; Yamaguchi M
Hematol Oncol; 2022 Oct; 40(4):667-677. PubMed ID: 35142384
[TBL] [Abstract][Full Text] [Related]
6. The correlation of clinicopathological features and prognosis in extranodal natural killer/T cell lymphoma: a report of 42 cases in the early stage.
Zeng L; Huang W; Cao Z; Zheng B; Liu X; Guo L; Feng X
Ann Hematol; 2019 Jun; 98(6):1467-1476. PubMed ID: 30895352
[TBL] [Abstract][Full Text] [Related]
7. Patterns of relapse after successful completion of initial therapy in primary central nervous system lymphoma: a case series.
Patel MP; Kirkpatrick JP; Johnson MO; Healy P; Herndon JE; Lipp ES; Miller ES; Desjardins A; Randazzo D; Friedman HS; Ashley DM; Peters KB
J Neurooncol; 2020 Apr; 147(2):477-483. PubMed ID: 32140975
[TBL] [Abstract][Full Text] [Related]
8. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
9. Central nervous system involvement in T-cell lymphoma: A single center experience.
Gurion R; Mehta N; Migliacci JC; Zelenetz A; Moskowitz A; Lunning M; Moskowitz C; Hamlin P; Horwitz S
Acta Oncol; 2016 May; 55(5):561-6. PubMed ID: 27046135
[TBL] [Abstract][Full Text] [Related]
10. Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma.
El-Galaly TC; Cheah CY; Bendtsen MD; Nowakowski GS; Kansara R; Savage KJ; Connors JM; Sehn LH; Goldschmidt N; Shaulov A; Farooq U; Link BK; Ferreri AJM; Calimeri T; Cecchetti C; Dann EJ; Thompson CA; Inbar T; Maurer MJ; Gade IL; Juul MB; Hansen JW; Holmberg S; Larsen TS; Cordua S; Mikhaeel NG; Hutchings M; Seymour JF; Clausen MR; Smith D; Opat S; Gilbertson M; Thanarajasingam G; Villa D
Eur J Cancer; 2018 Apr; 93():57-68. PubMed ID: 29477102
[TBL] [Abstract][Full Text] [Related]
11. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group.
Kwong YL; Kim WS; Lim ST; Kim SJ; Tang T; Tse E; Leung AY; Chim CS
Blood; 2012 Oct; 120(15):2973-80. PubMed ID: 22919026
[TBL] [Abstract][Full Text] [Related]
12. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
Schorb E; Finke J; Ferreri AJ; Ihorst G; Mikesch K; Kasenda B; Fritsch K; Fricker H; Burger E; Grishina O; Valk E; Zucca E; Illerhaus G
BMC Cancer; 2016 Apr; 16():282. PubMed ID: 27098429
[TBL] [Abstract][Full Text] [Related]
13. Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: elucidating the significance of systemic chemotherapy.
Guo Y; Lu JJ; Ma X; Wang B; Hong X; Li X; Li J
Oral Oncol; 2008 Jan; 44(1):23-30. PubMed ID: 17306611
[TBL] [Abstract][Full Text] [Related]
14. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
15. Central nervous system recurrence of systemic lymphoma in the era of stem cell transplantation--an International Primary Central Nervous System Lymphoma Study Group project.
Bromberg JE; Doorduijn JK; Illerhaus G; Jahnke K; Korfel A; Fischer L; Fritsch K; Kuittinen O; Issa S; van Montfort C; van den Bent MJ
Haematologica; 2013 May; 98(5):808-13. PubMed ID: 23144196
[TBL] [Abstract][Full Text] [Related]
16. Clinical Outcomes and Prognostic Factors of Up-Front Autologous Stem Cell Transplantation in Patients with Extranodal Natural Killer/T Cell Lymphoma.
Yhim HY; Kim JS; Mun YC; Moon JH; Chae YS; Park Y; Jo JC; Kim SJ; Yoon DH; Cheong JW; Kwak JY; Lee JJ; Kim WS; Suh C; Yang DH;
Biol Blood Marrow Transplant; 2015 Sep; 21(9):1597-604. PubMed ID: 25963920
[TBL] [Abstract][Full Text] [Related]
17. High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma.
Alvarnas JC; Negrin RS; Horning SJ; Hu WW; Long GD; Schriber JR; Stockerl-Goldstein K; Tierney K; Wong R; Blume KG; Chao NJ
Biol Blood Marrow Transplant; 2000; 6(3A):352-8. PubMed ID: 10905773
[TBL] [Abstract][Full Text] [Related]
18. A phase II prospective study of the "Sandwich" protocol, L-asparaginase, cisplatin, dexamethasone and etoposide chemotherapy combined with concurrent radiation and cisplatin, in newly diagnosed, I/II stage, nasal type, extranodal natural killer/T-cell lymphoma.
Jiang M; Zhang L; Xie L; Zhang H; Jiang Y; Liu WP; Zhang WY; Tian R; Deng YT; Zhao S; Zou LQ
Oncotarget; 2017 Jul; 8(30):50155-50163. PubMed ID: 28404973
[TBL] [Abstract][Full Text] [Related]
19. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.
Abrey LE; Moskowitz CH; Mason WP; Crump M; Stewart D; Forsyth P; Paleologos N; Correa DD; Anderson ND; Caron D; Zelenetz A; Nimer SD; DeAngelis LM
J Clin Oncol; 2003 Nov; 21(22):4151-6. PubMed ID: 14615443
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerance of pegaspargase-based chemotherapy in patients with nasal-type extranodal NK/T-cell lymphoma: a pilot study.
Wen JY; Li M; Li X; Chen J; Lin Q; Ma XK; Dong M; Wei L; Chen ZH; Wu XY
Asian Pac J Cancer Prev; 2014; 15(15):6275-81. PubMed ID: 25124611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]